Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.

Neuropsychobiology - 1 Jan 2009

Kobylecki Camilla J, Jakobsen Klaus D, Hansen Thomas, Jakobsen Ida V, Rasmussen Henrik B, Werge Thomas

Abstract excerpt

OBJECTIVE: The aim of the present retrospective pilot study was to examine the clinical impact of the cytochrome P450 (CYP) enzyme CYP2D6 poor metabolizer (PM) genotype in patients taking antipsychotic medication. The impaired metabolic capacity of the PM genotype results in higher steady-state plasma concentrations at a given dose, thus increasing the risk of toxic effects from medication. METHODS: We identified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Basal Ganglia Diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Cytochrome P-450 CYP2D6

Share to Medication Adherence

Share to Pilot Projects

Share to Schizophrenia

Share to Sequence Analysis, DNA

Source

Identifiers

PMID: 19521114
DOI: 10.1159/000223734

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.PMID 19521114Read ↗

Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?Semantic proximity Read ↗

CYP2D6 mutations and therapeutic outcome in schizophrenic patients.Semantic proximity Read ↗

Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.Semantic proximity Read ↗

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.Semantic proximity Read ↗

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.Semantic proximity Read ↗

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Semantic proximity Read ↗

Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.Semantic proximity Read ↗

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype.Semantic proximity Read ↗

CYP 2D6 polymorphism and antipsychotic therapy.Semantic proximity Read ↗

CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.Semantic proximity Read ↗

Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score.Semantic proximity Read ↗

Pharmacogenetics of antipsychotic-induced side effectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.